Is extracorporeal hypothermic machine perfusion of the liver better than the 'good old icebox'?

To underscore the advantages of hypothermic machine perfusion (HMP) in light of the recent discoveries. The phase I clinical trial of liver HMP has suggested superiority over static cold storage (SCS) preservation. The liver transplant arena has gained more sophisticated insights into the molecular mechanism and biomechanical understanding behind the benefits of HMP. Its ability to attenuate ischemia-reperfusion injury translates to reduction in ischemia-reperfusion injury with improved early allograft function. HMP has the potential to predict graft function as well as enable resuscitation of grafts from extended criteria donors. Targeted therapeutic interventions via HMP will further contribute to optimal preservation and reconditioning of the allografts. HMP's advantages do not merely derive from its mechanical forte in maintaining the microvasculature patent. It is also a versatile clinical tool with the ability to deliver metabolic substrates, antioxidants and therapeutic agents to the ex-vivo graft, dilution of waste products generated by inefficient or anaerobic respiration, intraoperative ex-vivo assessment and prediction of the graft's future performance posttransplantation. With demonstrated superiority over SCS, HMP holds promise for expanding the donor pool and becoming the gold standard for liver preservation.